@article{ETD,
      school = {Ph.D.},
      author = {Rosenstein Siegel, Sarah A.},
      url = {http://digitalcollections.ohsu.edu/record/7992},
      title = {Another brick in the wall: building epidemiologic evidence  of infectious risks by psoriasis therapy types},
      publisher = {Oregon Health and Science University},
      abstract = {Psoriasis is a chronic, inflammatory disease that affects  about 10 million individuals in the United States. New  psoriasis treatments target the dysregulated immune system  functions responsible for disease pathogenesis. However,  many of these immune pathways are also responsible for  protecting the body from fungal and bacterial infections.  Due to the increasing number of biologic therapies recently  approved to treat psoriasis, understanding the comparative  infectious risk associated with different biologic  therapies is of upmost importance.},
      number = {ETD},
      doi = {https://doi.org/10.6083/8336h247h},
      recid = {7992},
      address = {2020},
}